Comparison of humoral immune response in heterologous and homologous COVID-19 booster vaccine groups using CoronaVac and mRNA-based BNT162b2 vaccines
No Thumbnail Available
Date
2023
Authors
Atici, Serkan
Soysal, Ahmet
Gonullu, Erdem
Aydemir, Gokhan
Oner, Naci
Alan, Servet
Karabocuoglu, Metin
Journal Title
Journal ISSN
Volume Title
Publisher
Soc Brasileira Medicina Tropical
Open Access Color
OpenAIRE Downloads
OpenAIRE Views
Abstract
Background: Heterologous COVID-19 booster vaccination is an alternative strategy to homologous vaccination, especially in developing countries, due to shortages, delays, or unequal distribution of COVID-19 vaccines. We compared cohorts vaccinated with different vaccine combinations to investigate whether a heterologous booster dose of mRNA-based BNT162b2 vaccine boosts the immune response in individuals primed with the CoronaVac vaccine. Methods: Anti-RBD IgG is generally measured 4 weeks after primary immunization and 4 weeks after booster vaccination. Data on anti-receptor-binding domain (anti-RBD) IgG antibody titers and clinical characteristics were provided by infection control units. Results: The highest median anti-RBD IgG antibody titers (14589 AU/mL) after primary immunization was observed in the group vaccinated with two doses of BNT162b2 vaccine. Antibody titers were lower 4 months or more after the second CoronaVac vaccine dose in CoronaVac recipients with or without previous COVID-19. In the homologous COVID-19 booster vaccine group (primed with two doses of CoronaVac 4 weeks apart and a single booster dose of CoronaVac) the median anti-RBD titers decreased from 1025 to 242 AU/mL before the booster dose. In the heterologous group (primed with two doses of CoronaVac 4 weeks apart and a single booster dose of BNT162b2), the median anti-RBD titer increased to 31624 AU/mL, a 132-fold increase, 16 days after the booster dose. Conclusions: After the second dose of CoronaVac, protective neutralizing antibody levels decrease over time, and a booster dose is required. Heterologous COVID-19 booster vaccination with BNT162b2 is effective at boosting neutralizing antibody levels.
Description
Gonullu, Erdem/0000-0002-6833-5646; ATICI, Serkan/0000-0002-3329-1866; Alan, Servet/0000-0002-8228-6350; karabocuoglu, metin/0000-0003-2854-0562
Keywords
COVID-19 vaccines, CoronaVac, BNT162b2, Booster dose, Heterologous vaccination schedule, Homologous vaccination schedule
Turkish CoHE Thesis Center URL
Fields of Science
Citation
0
WoS Q
Q3
Scopus Q
Q3
Source
Volume
56